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Abstract
A PROPOSED METHOD FOR NONINVASIVE ASSESSMENT OF ENDOTHELIAL DAMAGE
Kirsten A. Menn, Robert B. Schonberger, William L. Worden, Kaveh Shahmohammadi, Tyler J.
Silverman, Robert Stout, Kirk Shelley, David G. Silverman, Department of Anesthesiology, Yale
University, School of Medicine, New Haven, CT.
Transdermal microvascular studies of endothelial cell function have typically used iontophoresis
to facilitate acetylcholine absorption, but iontophoresis introduces an important confounding stimulus that
can alter the behavior of the microvasculature. This study examines a non-iontophoretic technique for
transdermal microvascular studies using acetylcholine and nitroglycerin and demonstrates a relatively
impaired vasodilatory response to these substances in a population with known microvascular pathology.
Ten subjects without known vascular disease or diabetes were recruited for laser Doppler
flowmetry (LDF) monitoring. Topical acetylcholine chloride, nitroglycerin, and placebo were applied to
subjects’ foreheads directly below LDF probes. Readings increased by averages of 406% (245%-566%)
and 36% (26%-46%), respectively, at the acetylcholine and placebo sites (p=0.005 by Wilcoxon Signed
Rank Test (WSRT)); and they increased by 365% (179%-550%) at the nitroglycerin site (p=0.005 by
WSRT versus placebo; p=0.6 versus acetylcholine).
Ten diabetic subjects were also monitored. Mean percent increases in blood flow were 156%
(91%-221%) and 116% (79%-153%), respectively, at the acetylcholine and nitroglycerin sites, vs. 21% (CI
4-37%) at the placebo site (p=0.005 by WSRT for placebo versus each active site). Diabetics’ responses at
both active sites were significantly impaired relative to healthy subjects (p<0.001 and p=0.009,
respectively, by Mann-Whitney U Test)
Topical acetylcholine and nitroglycerin induced significant local vasodilatory responses without
requiring iontophoresis in both healthy and diabetic subjects. Diminished responses were noted in diabetic
patients. This technique may constitute a minimally invasive way to interrogate the microvasculature
including its responses in various disorders and the microcirculatory changes induced by therapeutic
interventions.
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INTRODUCTION
Knowledge of endothelial cell biology has grown dramatically over the
past two decades. Once thought to be simply a static physical barrier between
the blood and other tissues, the endothelium is now known to participate in a
wide range of physiologic processes. Normal endothelial functions include
regulation of blood pressure and flow, production and growth of new vessels,
mediation of capillary transport, and alteration of inflammation.
Of particular clinical significance is the role the endothelium plays in the
regulation of vascular homeostasis, which allows adequate end‐organ perfusion
through the continuous control of vessel tone and blood flow and the
constitutive inhibition of thrombosis. Endothelial cells modulate vascular
smooth muscle tone through the production, secretion, removal, or metabolic
degradation of vasoactive substances, such as nitric oxide, prostacyclin,
endothelin, and platelet‐activating factor. These substances are capable of
dilating or constricting vascular beds. In addition to synthesizing and
responding to their own vasoactive mediators, endothelial cells may transduce
signals from circulating vasodilators and constrictors such as thrombin,
bradykinin, ADP and ATP 1 .
Endothelial dysfunction has been observed in patients with a wide variety
of diseases including diabetes 2, 3 , atherosclerosis 4 , hypercholesterolemia 5, 6 ,
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homocystinuria 7 , and hypertension 8, 9 , 10 . Individuals with dysfunctional
endothelium show impaired endothelium‐dependent vasodilatation or flow
mediated dilatation as shown by decreased response to the administration of
acetylcholine. Similar dysfunction has been observed in subjects with advanced
age 11 , exposure to cigarette smoke 12, 13 , sedentary life style 14 , and those who have
undergone organ transplantation 15 . Endothelial dysfunction appears to be a
widespread systemic process with correlations existing between impairment in
the coronary arteries and in the peripheral circulation10, 16 , 17 , 18 .
In addition to its association with a variety of pathological conditions,
endothelial dysfunction may serve as a predictor of acute vascular conditions.
Several studies have suggested a direct connection between endothelial
dysfunction and cardiovascular events, such as myocardial infarction or sudden
death, in patients with and without coronary disease 19, 20 , 21 . Endothelial
dysfunction is also associated with the development of transplant vasculopathy.
In a study of 73 patients who underwent heart transplantation, the presence of
endothelial dysfunction predicted the development of complications such as
graft failure or sudden death 22 .
Impaired endothelial function is also thought to play a key role in the
development of many of the secondary complications of diabetes mellitus, such
as retinopathy, accelerated atherosclerosis, microvascular disease, nephropathy,
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neuropathy, and impaired wound healing 23, 24 . Persistent exposure to
hyperglycemia may lead to endothelial damage through the production of
reactive oxygen intermediates. Hyperglycemia also activates protein kinase C
and the aldose reductase pathway, resulting in an accumulation of sorbitol and
diminished levels of myo‐inositol23, 24. In addition, hyperglycemia induces the
formation of advanced glycation end products (AGEs) that modify structures on
erythrocytes. This modification allows erythrocytes to engage a specific receptor,
RAGE, (receptor for advanced glycation end products) 25 . AGE‐RAGE
interactions promote vascular permeability and increased expression of pro‐
inflammatory cytokines, thrombogenic factors, and cell adherence molecules
which can aggravate and accelerate the development of endothelial lesions 26, 27 .
When certain secondary complications appear in a diabetic patient, other
complications are likely to be present, as well. For example, one study found
that in diabetic subjects with systolic blood pressures of at least 145 mm Hg, the
incidence of retinal disease was more than twice that in diabetic subjects with
systolic pressures of less than 125 mm Hg 28 . Other studies have found a
correlation between the presence of retinopathy and nephropathy 29, 30 . Therefore
by the time a diabetic patient presents with retinopathy, dysfunctional
endothelium is already likely to be present on a widespread basis.

3

The presence endothelial dysfunction in the early phases of multiple
diseases has a number of important clinical implications. It might be assumed
that at this early stage that arterial wall damage would be least extensive and
most likely to be reversible. There now exists a wide variety of different
therapies that improve endothelial function. HMG‐CoA reductase inhibitors
(statins ) 31, 32 , diet modification 33 , 34 , weight loss 35 , aerobic exercise 36 , aspirin 37 ,
angiotensin converting enzyme (ACE) inhibitors 38, 39 , angiotensin II receptor
blockers 40, 41 , 42 , and estrogen therapy 43 have been associated with ameliorated
endothelial dysfunction.
If compromised endothelial function could be easily and accurately
identified in subjects, therapies could be initiated and monitored, and potential
damage could thereby be prevented, retarded, or diminished. Unfortunately, no
methods for such screening currently exist. Unlike other organs, the
endothelium is not visible on imaging studies, nor is endothelial damage is
associated with predictable changes in blood chemistry.
At the present time, several methods are used to assess endothelial
dysfunction in the research setting. These techniques include quantitative
angiographic measurement of changes in the coronary artery flow in response to
intracoronary acetylcholine or serotonin infusions, ultrasound measurement of
the brachial artery after hyperemia induction with blood pressure cuff occlusion
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and flow‐mediated dilatation, and forearm blood flow measurement by venous
plethysmography using intraarterial infusion of a cholinergic stimulus. These
methods utilize various stimuli to enhance the release of endothelial nitric oxide
and cause artery dilatation 44, 45 .
Disadvantages of angiography and intra‐arterial injection techniques
include their invasive natures, which make them inappropriate for studies
involving asymptomatic subjects or for use as screening tests. Brachial artery
ultrasound, although non‐invasive and non‐radioactive, is considered to be a
relatively difficult technique for technicians to master, and the results and
interpretations tend to be inconsistent and difficult to reproduce 46, 47 .
Laser Doppler flowmetry (LDF) and iontophoresis have also been used to
assess endothelial function in the research setting. LDF is a non‐invasive
technique that has been used to monitor and study the continuous flow of
cutaneous or peripheral blood. It uses the Doppler shift in laser light secondary
to moving red blood cells to provide a value (flux) which has been validated as
proportional to blood flow. The volume measured is limited to approximately
the 1 mm3 of tissue beneath a surface probe. Since the sampled volume is so
small, LDF can indicate localized perfusion without being influenced by
surrounding tissues 48 . This methodology has potential of becoming an efficient
and useful non‐invasive tool for assessing endothelial functioning.
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In order for the potential role of LDF in endothelial assessment to be better
explored, it would likely benefit from being paired with a different method of
drug delivery. Although iontophoresis is less invasive than intra‐arterial
injections, it has significant limitations. A slight risk of electrical burns is
associated with this technique, and the electric current itself has been shown to
cause vasodilatation 49 . Even when potential vasodilatation from the current is
taken into account when analyzing data, effects vary among different vehicles
and drugs 50,51 , and tend to confound studies 52 .
Given the limitations of current methods of endothelial assessment, a
simple, reliable, noninvasive test for identifying endothelial dysfunction would
potentially have relevant clinical applicability. Such a test might identify
presymptomatic subjects at high risk for atherosclerotic complications and
therefore allow initiation of primary preventive treatments. It could also
potentially allow characterization of disease states and monitoring the responses
to therapies.
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PURPOSE AND HYPOTHESIS
Initial unpublished trials by our investigative team identified 100‐300%
increases in local blood flow when acetylcholine chloride eye drops (Miochol‐
E,TM Novartis, East Hanover, NJ) were applied to the forehead under an LDF
probe. This targeted administration of small amounts of a topical agent seemed
to affect local microcirculatory flow at the site of application without significant
systemic effects. However, the presence of mannitol in the Miochol preparation
may have affected local vascular changes.
These results prompted a decision to explore the effects of a transdermal
preparation of pure acetylcholine chloride powder dissolved in water with the
hope of inducing similar microvascular dilation without the effects of Miochol.
In addition to this endothelium‐dependent test of vasodilation, we used a
commercially available translucent nitroglycerin patch to test endothelium‐
independent vasodilation in a similar manner.
We proposed that endothelial dysfunction may be identified and
characterized with noninvasive assessment of microcirculatory responses to
transdermal administration of acetylcholine and nitroglycerin using laser
Doppler flowmetry. It was anticipated that patients with known endothelial
dysfunction would show impaired vasodilatation when given these topical
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vasoactive agents when compared to healthy volunteers. By comparing the
different responses of healthy volunteers to diabetic patients with documented
retinopathy, we hoped to describe the various responses and possibly correlate
with the presence of disease. With adequate data, not only could such testing
potentially allow assessment of disease extent and monitoring of therapeutic
interventions, but could also allow earlier identification of endothelial
dysfunction in asymptomatic subjects.
We hoped these methods would provide primary results that would
encourage future testing, and possibly eventually become the foundation for a
future test of endothelial function that would be more comfortable, simple, safe,
and reliable than tests previously described.

METHODS
After IRB‐approved trials with acetylcholine in multiple diluents with a
range of hydrophilicity, we elected to administer transdermal acetylcholine by
placing acetylcholine chloride powder dissolved in water on a translucent
adherent surface. Then, with IRB approval, 10 healthy volunteers and 10
patients with diabetic retinopathy were recruited for LDF measurements of
forehead perfusion at sites of transdermal application of acetycholine,
nitroglycerin, and placebo.
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For each session, after informed consent was obtained, subjects lay on a
bed in a semi‐recumbent position in a temperature‐controlled room (24+1
degrees Celsius). A three‐lead electrocardiogram and a non‐invasive brachial
artery blood pressure cuff were applied. Local forehead skin oils were decreased
by wiping the skin lightly with an alcohol swab, followed by wet and dry gauze.
Two minutes later, three Double‐Stick Discs (3M Health Care, Neuss, Germany)
with an overall diameter of 38.1 mm and a central hole diameter of 8.7‐mm were
placed on the forehead. These discs served as an adherent base onto which laser
Doppler probes were placed as well as to define the 59.4 mm2 area for drug
application.
The acetylcholine solution was freshly prepared for each session by
mixing 100‐mg of acetylcholine chloride (Spectrum Chemical; New Brunswick,
NJ) with 0.6‐mL high pressure liquid chromatography (HPLC) grade water to a
final volume of 0.7‐mL and molar concentration of 786.4 M. Then, 0.02‐mL (2.8
mg) of this concentrated acetylcholine solution was spread on a double‐stick
clear disk (diameter 12.6 mm, area 124.7‐mm2). The dry side of the acetylcholine
“patch” was adhered to the bottom of a laser Doppler flowmeter probe (PF 5010
with Probe Model 407, Perimed, Sweden). A placebo drug patch was made in
the same way with 0.02‐mL of HPLC‐grade water instead of acetylcholine
solution.
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The nitroglycerin patch was obtained by using a standard hole‐punch to
cut a 6‐mm diameter (28.3‐mm2 area) section of a 0.6 mg/hr MinitranTM
nitroglycerin patch (3M, Minnesota). The patch is designed for homogeneous
delivery of drug at a rate of 0.03‐mg/hour per 100‐mm2 area of patch. The small
patch area in our study was thought to deliver at a rate of approximately 0.008‐
mg/hr. The nitroglycerin patch then was placed onto a double stick disc and
positioned over a laser Doppler sensor in a similar manner to the acetylcholine
patch.
The three laser Doppler probes with patches attached were adhered onto
the three double‐stick discs on the forehead so as to enable undisturbed
monitoring and drug delivery. LDF monitoring was performed continuously at
each site until a vasodilatory plateau was maintained for >3 minutes or for a
maximum of 20 minutes. Data were collected at a rate of 1000 Hz using Chart for
Windows (ADInstruments, Colorado Springs, Colorado). All LDF sensors were
calibrated using a motility standard (Perimed, Sweden) twice during the three‐
month study period.
The local microvascular effects of transdermal acetylcholine and
nitroglycerin were first tested in 10 healthy volunteers (7 males, 3 females; mean
age 36.1, range 19 to 56 years) without known vascular disease or diabetes. The
effects also were tested in 10 diabetic subjects (3 males, 7 females; mean age 56.5,
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range 40 to 73 years) recruited in the Yale Eye Center. Nine of the 10 diabetic
subjects had documented microvascular retinal pathology by fluorescein
angiography; the other did not undergo angiography. Patients were excluded
from the study if they had taken nitrates in the previous 48 hours or if they had
already received mydriatic eye drops on the study day. Other than these
restrictions, subjects were not asked to alter their diet or medications prior to the
study.
An investigator blinded to the status of the subject and to the nature of the
study site assessed the laser Doppler tracing at each study site. The pre‐study
trials had indicated that, within 10 seconds of probe application, a steady
baseline interval was consistently obtainable and that a progressive drug‐
induced rise in flow with both acetylcholine and nitroglycerin was noted to
begin as soon as 30 seconds after probe application. This enabled a 20‐sec
baseline period to be obtained, without the need to remove the probe for
subsequent drug application. Each probe remained in place for up to 20 minutes.
The drug‐induced increase in flow in the present study was determined
by comparing the mean during the lowest 10‐second interval during baseline
period with the mean during the maximum 10‐second interval after a plateau
was reached. If no distinct rise in blood flow was evident, then the highest 10‐
second interval that occurred beyond the first two minutes of readings was used.
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Data are presented as mean percent increase in LDF voltage with 95%
confidence intervals (CI). Since the primary goal was to test whether the means
of delivery and testing introduced herein generate and delineate a consistent
vasodilatory response, the primary endpoint was the change in LDF voltage after
transdermal application of active drug versus placebo in healthy volunteers.
This was accomplished with the Wilcoxon Signed Rank Test (WSRT), using SPSS
for Macintosh (SPSS, Inc. Chicago, IL). Previous investigations with
iontophoretic delivery of acetylcholine had generated increases in skin blood
flow ranging from 160 to 710%, depending on concentration of drug and
iontophoretic current13, 53 .
Given these data and our preliminary trials, we anticipated at least a 100%
increase in blood flow (with a standard deviation of 50%) at the sites of active
patches versus a 20% difference (with a standard deviation of 10%) at sites of
placebo application (LDF readings have temporal variation even under baseline
conditions, a feature that would be emphasized by our comparison between the
highest 10‐second interval after drug application with the lowest 10 second
interval at baseline). In order to identify the difference between the active and
placebo patches with an alpha of 0.025 and a beta of 0.8, we calculated that a
sample size of seven subjects would be required. P‐values greater than 0.05 are
reported as not significant (NS); for values <0.05, the actual value is reported.
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Secondary endpoints were also assessed, with the realization that our
study design was not tailored to these comparisons. First, the effects of the single
dose of acetylcholine were compared to those of the single dose of nitroglycerin
in the healthy volunteers, with the differences analyzed using WSRT. Second, a
preliminary assessment of the response in the healthy volunteers versus the 10
diabetic patients (who were older with varied medical conditions and
medications) were compared using the Mann‐Whitney U Test (MWUT).

RESULTS (FIGURES 1‐3)
Healthy Volunteers, Acetylcholine
Acetylcholine induced a visible rise in LDF voltage within two minutes of
administration. This was evident with respect to mean flow, as well as with
respect to the amplitude of the pulsation coincident with each heart beat. This
elevation of blood flow persisted throughout the duration of the study session.
Readings increased, on average, by 406% (245%‐566%) at the acetylcholine sites
and 36% (26%‐46%) at the placebo sites (p=0.005 by WSRT).

Diabetic Patients, Acetylcholine
In the diabetic group, acetylcholine also induced a visible rise in LDF
voltage within approximately two minutes of administration. The mean percent
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increases in blood flow were 156% (91%‐221%) at the acetylcholine sites,
compared to 21% (4%‐37%) at the placebo sites (p=0.005 by WSRT). While the
vasodilatory responses were significantly greater than those observed with
placebo, they were less than those in the healthy volunteer group.

Healthy Volunteers, Nitroglycerin
Nitroglycerin administration caused a marked rise in LDF voltage in the
healthy volunteer group, similar to that seen with acetylcholine administration.
Within two minutes of drug application, blood flow at the treatment sites rose
and remained increased throughout the remainder of the study session. The
average increase from baseline was 365% (179%‐550%) compared to the 36%
(26%‐46%) increase at the placebo site (p=0.005 by WSRT versus placebo; p = NS
versus acetylcholine).

Diabetic Patients, Nitroglycerin
Similar to the response seen with acetylcholine, nitroglycerin‐induced
vasodilatory responses in diabetics were significantly greater than to placebo, but
less than in healthy volunteers. Mean percent increases in blood flow were 116%
(79%‐153%) at nitroglycerin sites vs. 21% (CI 4‐37%) at the placebo site (p=0.005
by WSRT).
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Overall, the responses of the diabetic patients to acetylcholine and
nitroglycerin did not differ significantly from each other (p=NS by WSRT). The
diabetics’ responses at each active site were significantly impaired relative to
healthy subjects (p<0.001 and p=0.009, respectively, by MWUT).

DISCUSSION
This investigation yielded several unique findings and implications for
further study. First, by using topical acetylcholine and nitroglycerin in
conjunction with LDF, it was possible to induce and observe microvascular
dilatation non‐invasively. Second, distinct differences in degrees of dilatation
were noted between healthy volunteers and patients with assumed endothelial
dysfunction. This novel method appeared to allow sufficient uptake of
vasoactive drugs for stimulation of clear local effects without detectable systemic
changes. Complications associated with iontophoretic electric currents were
avoided by using this method of administration. While the local vasodilatory
effects of transdermal nitroglycerin have long been appreciated and used in the
clinical setting, a comparable response to non‐iontophoretic transdermal
acetylcholine has not been reported 54 .
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Acetylcholine and nitroglycerin were chosen for this study on the basis of
the likelihood that they would produce local vasodilatation through distinct
endothelium dependent and independent mechanisms, respectively. It was
hypothesized that if this experimental method were to provide the basis for a
possible future clinical test of endothelial function, not only would dilatation be
noted after application of the vasoactive agents, but different degrees of response
should also occur in individuals with varying disease states.
In this study, it was observed that patients with diabetic retinopathy
showed significantly less dilatation when given approximately equal amounts of
both acetylcholine and nitroglycerin as healthy volunteers. As the diabetic group
was presumed to have widespread endothelial dysfunction, it was predicted that
their reactions would be significantly less than those of healthy volunteers,
particularly to drugs whose effects are mediated via endothelium‐dependent
mechanisms (e,g., acetylcholine). In order best to explain these findings and
explore their implications, it would be helpful to revisit the results and the
physiologic basis for the vasodilatation associated with nitroglycerin and
acetylcholine.
Nitric oxide (NO) produced from the endothelium is a particularly
important component of vascular homeostasis. It is formed from the oxidation of
L‐arginine to L‐citrulline by endothelial nitric oxide synthase (eNOS) 55, 56 and is
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synthesized constitutively by intact endothelium. NO functions to maintain low
arterial tone at rest by binding to guanylyl cyclase, thereby increasing
intracellular cyclic guanosine monophosphate levels, reducing intracellular
calcium, and consequently relaxing smooth muscle cells 57, 58 , 59 , 60 . The same
pathway is involved in the mechanism of action of exogenous nitrovasodilators,
such as sodium nitroprusside and nitroglycerin.
Additional endogenous NO release from normal endothelium can be
stimulated by increased blood flow 61 and by bradykinin, thrombin, acetylcholine,
and a variety of other circulating agents that activate specific endothelial cell
membrane receptors 62 . In additional to its vasodilatory effects, NO inhibits
platelet adhesion, activation, secretion, and aggregation, and encourages platelet
disaggregation. Leukocyte recruitment and adhesion to the endothelium are
controlled in part by NO through its inhibition of smooth muscle cell migration
and proliferation 63, 64 , 65 , 66 . The half‐life of unbound NO is in the order of
seconds, but a prolonged bioactivity may be conferred by its binding and the
nitrosylation of albumin or other plasma proteins 67 . Degradation of nitric oxide
by heme‐mediated oxidation is a major route of nitric oxide inactivation, with the
production of nitrite and nitrate as end products 68 .
Whereas the generation of NO is endothelium‐dependent, the
vasodilatory responses elicited by NO are considered to be “endothelium‐
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independent” since such responses have been thought to be preserved regardless
of the presence or absence of intact endothelium. Despite this preservation,
however, some patients with endothelial dysfunction have been observed to
have a reduced endothelial response to exogenous sources of NO, such as
nitroglycerin 69 . This is thought to be indicative concomitant endothelium‐
independent smooth muscle dysfunction.
The data in this study show that topical administration of nitroglycerin
induced an average 365% (179%‐550%) increase in blood flow in healthy
volunteers and 116% (79%‐153%) increase in diabetic patients. These results
indicate that significant local vasodilatory responses were elicited in both groups
without requiring iontophoresis. Furthermore, the degrees of reaction were
distinctly different between the two groups, with diminished responses noted in
diabetic patients. These findings are consistent with previous reports of patients
with endothelial dysfunction having reduced endothelial responses to
nitroglycerin (above), and may indicate the presence of smooth muscle
dysfunction as well as endothelial dysfunction in the diabetic population.
Stimulation of normal endothelium by acetylcholine also produces
vasorelaxation. This is thought to be achieved through the release of NO as well
as another endothelium‐derived relaxing factor (EDRF). This EDRF causes
hyperpolarization of underlying smooth muscle by increasing potassium ion
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conductance and activating the cyclic guanosine monophosphate (cGMP)
pathway 70, 71 . However, if the endothelium is removed experimentally,
acetylcholine causes a seemingly paradoxical constriction of blood vessel. This is
the result of acetylcholine directly stimulating medial smooth muscle cells. A
similar reaction also occurs in vivo in vessels with denuded intima or
dysfunctional endothelium. The vasodilatory responses elicited by acetylcholine
have therefore been regarded as “endothelium‐dependent”, since they were
thought to produce vasodilation only in the presence of intact endothelium.
More recent studies, however, have shown that the classification of
acetylcholine as a mediator of endothelium‐dependent vasodilation is not
absolute in all settings. For example, iontophoretic application of acetylcholine
has been shown to induce vasodilation partially through prostanoid mediated
pathways that are independent of endothelial cell function 72 . The extent to
which topical acetylcholine‐induced microvascular dilation may reflect
endothelial cell function remains to be delineated, as does the effect of different
doses of acetylcholine on individuals’ responses.
The data in this study show that topical administration of acetylcholine
induced an average 406% (245%‐566%) increase in blood flow in healthy
volunteers and 156% (91%‐221%) increase in diabetic patients. Increases at
placebo sites were 36% and 21% for healthy and diabetic groups, respectively. It
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was again concluded that transdermal administration of acetylcholine caused
local vasodilatory responses in both groups without requiring iontophoresis.
Furthermore, similar to the responses to nitroglycerin, the differences in extent of
vasoreactivity between the two groups were significant enough to conclude that
the presence of endothelial dysfunction will yield diminished responses.
In addition to its non‐invasive nature, this novel method has several other
advantages. Unlike brachial artery ultrasound, the technique is relatively simple
and requires minimal training on the part of the technician. The setup and
cleanup time is in the order of minutes, and the equipment itself is portable. The
test is also more comfortable for patients than brachial artery ultrasound during
reactive hyperemia, as it does not require the five‐minute occlusion of arterial
flow.
In terms of the reagents used, both acetylcholine and nitroglycerin are
rapidly broken down. This makes them well‐suited to transdermal application
for local microvascular testing without systemic effects. Furthermore, the
transdermal patches themselves are amenable to placement in regions of the
body for which the more elaborate iontophoresis apparatus may not be suitable
or would be deemed undesirable. This could allow for testing of microvascular
reactivity in multiple areas of the body.
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The results described herein can be thought of as very encouraging, but
preliminary. Limitations of the study warrant attention before drawing
conclusions and implications. The translucent patch design in this study made it
possible to obtain a short baseline reading in the initial period of drug
application without moving the probe. The technique, however, might be
improved by a delayed‐release patch that would allow for a more prolonged
baseline measurement. In addition, LDF readings are generally characterized by
spatial variation, and it is probable that the described patch technique would be
prone to such variation, as well. Spatial variation could possibly be reduced with
larger LDF probes which encompass more than the 1‐3 arteriolar‐capillary
networks that typically are interrogated by a typical LDF probe 73 .
As previously mentioned, endothelial function is affected by many factors.
A decline in endothelial function has been observed with normal aging. The
phase of a womanʹs menstrual cycle also may affect vasoreactivity. It would
therefore be advantageous to conduct more studies using this technique where
the groups being compared are carefully age‐matched and gender‐matched. If
pre‐menopausal female subjects were to be used, it would be best to attempt
performing the studies during the same phases of their menstrual cycles.
Another limitation of this study involves many of the diabetic patients
having already been exposed to interventions shown to affect endothelial
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function. HMG‐CoA reductase inhibitors (statins) , have been associated with
ameliorated endothelial function in both young patients with Type 1 diabetes 74
and elderly patients with Type 2 diabetes, with or without mild
hypercholesterolemia 75 . These effects have been observed as early as three days
after the initiation of therapy, and appear to be independent of observable
changes in lipid levels. Diet modification, , weight loss, aerobic exercise, aspirin,
angiotensin converting enzyme (ACE) inhibitors38, , angiotensin II receptor
blockers, , , and estrogen therapy have also been shown to improve endothelial
function in certain subjects, as have supplementation with vitamins C, E, folate,
and 5‐methyltetrahydrofolate 76, 77 .
As the diabetic patients in the study were recruited from a clinic where
they were receiving treatment for retinal disease, most individuals had been on
one or several medications known to improve endothelial function. Some had
been on such medications for many years. This would have certainly affected the
results of this study, yet it would not have been ethical to request or instruct
patients to discontinue proven protective medications. Therefore, a study
recruiting healthy control subjects and patients with assumed endothelial
dysfunction who have not yet started endothelial‐ameliorating medications
would likely show more dramatic differences in vasoreactivity between groups.
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The limitations, though required to note for potential future studies, do
not necessarily prevent several important conclusions. One of the primary goals
of this investigation was to determine whether transdermal administration of
vasoactive drugs would allow sufficient absorption to induce vasoactive changes
without systemic effects. The vasodilatation associated with the acetylcholine
and nitroglycerin patches compared to placebo patches was indeed adequate to
assume directly related changes. A second goal was to compare the amount of
dilatation between two groups to assess whether individuals with assumed
endothelial dysfunction showed compromised vasoreactivity compared to
healthy subjects. Although it is not possible to quantify the specific degrees of
dysfunction based on our results, given the substantially diminished responses
in the diabetic group, it is reasonable to conclude that this method successfully
identified the presence of endothelial dysfunction within that group.
In conclusion, the present data suggest that examining vasoreactivity with
transdermal acetylcholine and nitroglycerin may be justified. That endothelial
dysfunction is associated with acute complications and is seen in the early phases
of multiple diseases implies that it would be valuable to identify and treat such
dysfunction. A simple, non‐invasive test to screen for presence of endothelial
dysfunction could theoretically permit earlier identification of such dysfunction
in asymptomatic subjects. It might be assumed that at this early stage, the

23

arterial wall damage would be least extensive and most likely to be reversible.
Theoretically, if therapeutic interventions are initiated before the damaging
effects of the individual diseases manifest, it might be possible to prevent or
retard potential damage. Even in advanced disease, modification of endothelial
dysfunction might decrease the propensity to vasoconstriction, thrombosis, or
both, and thereby decrease the risk of acute complications, such as
cardiovascular events. Serial testing of endothelial function may also be a useful
measure to monitor and guide therapy, once initiated.
With further elaboration, this technique may constitute a useful and
minimally invasive way to assess endothelial function. With development and
refinement, perhaps such a test could provide information such as the
quantifiable extent of dysfunction or areas of particular concern. Although
further studies are indicated in order to develop a reliable clinical test that would
be appropriate for such applications, this investigation provided evidence that
such studies may indeed be worth pursuing.
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Figure 1: Representative data from a healthy subject illustrating readings at the
acetylcholine site (top row), nitroglycerin site (middle row), and placebo site
(bottom row). Entire 20 minute study period is shown in the left hand column;
10 seconds at baseline and 10 seconds during the plateau phase are shown in the
middle and right hand columns, respectively. Prompt increases in blood flow at
the sites of transdermal acetylcholine and transdermal nitroglycerin application
are seen. This is manifested not only by an increase in mean flow but also in the
amplitude of each pulsation at the cardiac frequency.
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Figure 2: Boxplots of percent change in blood flow in healthy subjects at sites of
acetylcholine, nitroglycerin, and placebo patches. The box incorporates the data
between the 25th and 75th percentiles; the line within the boxes is the median; the
whiskers on either side show the full range of data values to a maximum of 1.5
times the interquartile range (if there had been points beyond such a range, they
would have been represented as individual dots and considered outliers). P=.005
for both drugs versus placebo.
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Figure 3: Boxplots of percent change in blood flow in patients with diabetes at
sites of acetylcholine, nitroglycerin, and placebo administration (p=.005 for both
drugs versus placebo).
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